Organ-on-Chip Market
The global Organ-on-Chip Market was valued at USD 272.0 million in 2025 and is projected to reach USD 342.5 million in 2026. The market is expected to reach USD 2.5 billion by 2036, registering a CAGR of 22.2% during the forecast period (2026–2036).
- Published
- Aug 2026
- Pages
- 457
- Format
- PDF + Excel
- Report ID
- MR-2149
- Base year
- 2025
- 2025 · BASELINE
- $272.0M
- 2036
- $2.50B
- CAGR 2026–2036
- 22.2%
2025 baseline · 2026–2036 forecast at 22.2% CAGR · hover a bar for the value
Key highlights
The global Organ-on-Chip Market is projected to reach USD 2.5 billion by 2036, driven by increasing demand for alternatives to animal testing, rising R&D costs in drug discovery, and growing regulatory acceptance of microphysiological systems as valid preclinical evidence.
North America is expected to account for the largest market share in 2026, while Asia-Pacific is projected to register the fastest growth during the forecast period.
By organ type, Liver-on-Chip is expected to account for the largest market share, whereas Multi-Organ-on-Chip platforms are projected to witness the fastest growth through 2036.
The FDA Modernization Act 2.0, signed into law in December 2022, removed the longstanding statutory requirement that safety and efficacy data for new drugs come specifically from animal studies, explicitly naming organ chips and microphysiological systems as qualifying alternatives.
The NIH's National Center for Advancing Translational Sciences has invested more than USD 140 million since 2012 in developing and validating tissue chip technologies through its Tissue Chip for Drug Screening program.
In July 2025, the NIH announced it would no longer create new funding opportunities for projects focused solely on animal testing, further reinforcing regulatory and funding momentum toward organ-on-chip and other new approach methodologies.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026–2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 22.2% |
| Format | PDF, Excel & Cloud Portal · 457 pages |
| Market Size (Value) in 2026 | USD 342.5 Million |
| Market Size (Value) in 2036 | USD 2.5 Billion |
| Segments Covered | By Organ Type: Liver-on-Chip, Lung-on-Chip, Heart-on-Chip, Kidney-on-Chip, Brain-on-Chip, Gut-on-Chip, Skin-on-Chip, Bone & Musculoskeletal-on-Chip, Pancreas-on-Chip, Tumor-on-Chip, Reproductive System-on-Chip, Other Organ Types. · By Type: Single-Organ-on-Chip, Multi-Organ-on-Chip, Human-on-Chip, Tissue-on-Chip, Disease-on-Chip, Tumor-on-Chip. · By Product & Service: Products (Organ-on-Chip Devices, Microfluidic Chips, Instruments, Consumables), Services (Organ-on-Chip Testing Services, Drug Screening Services, Toxicology Testing Services, Disease Modeling Services, Platform Development Services, Data Analysis Services, Contract Research Services). · By Technology: Microfluidic-Based Platforms, Membrane-Based Platforms, Hydrogel-Based Platforms, 3D Bioprinting-Based Platforms, Organoid-Based Platforms, iPSC-Based Platforms, Sensor-Integrated Platforms, Imaging-Integrated Platforms, AI-Integrated Platforms. · By Cell Source: Primary Human Cells, Immortalized Cell Lines, Stem Cells (Embryonic Stem Cells, Induced Pluripotent Stem Cells), Patient-Derived Cells, Genetically Engineered Cells, Animal-Derived Cells. · By Application: Drug Discovery & Development, Toxicology Testing, Disease Modeling, Personalized & Precision Medicine, Regenerative Medicine, Cosmetic & Personal Care Testing, Chemical & Environmental Toxicology, Other Applications. · By End User: Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinical Institutions, Cosmetics & Personal Care Companies, Chemical Companies, Government & Regulatory Organizations, Other End Users. |
| Countries Covered | North America: U.S., Canada. · Europe: Germany, U.K., France, Netherlands, Switzerland, Belgium, Sweden, Italy, Spain, Rest of Europe. · Asia-Pacific: China, Japan, South Korea, India, Singapore, Australia, Taiwan, Rest of Asia-Pacific. · Latin America: Brazil, Mexico, Argentina, Rest of Latin America. · Middle East & Africa: Israel, UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa. |
| Key Companies | Emulate, Inc., MIMETAS B.V., CN Bio Innovations Ltd., TissUse GmbH, InSphero AG, Nortis, Inc., AlveoliX AG, Hesperos, Inc., Kirkstall Ltd., Cherry Biotech, AIM Biotech Pte. Ltd., SynVivo, Inc., Quris-AI, and Altis Biosystems, Inc. |
Report overview
Segments covered: organ type, type, product & service, technology, cell source, application, end user.
The Organ-on-Chip Market comprises microfluidic cell culture devices engineered to replicate the structure, function, and physiological environment of human organs and tissues at a miniaturized scale. These platforms integrate microfluidic channels, cell culture chambers, extracellular matrix scaffolds, membrane systems, and embedded sensors to recreate dynamic, organ-specific conditions such as fluid flow, mechanical strain, and cell-cell interfaces, enabling researchers to study drug metabolism, toxicity, and disease processes in a human-relevant model that more closely predicts clinical outcomes than conventional 2D cell culture or animal models.
The market is being fundamentally reshaped by a rapid shift in U.S. regulatory policy toward reducing reliance on animal testing in drug development. The FDA Modernization Act 2.0, signed into law in December 2022, removed the requirement for certain preclinical studies to rely specifically on animal testing and opened the pathway for alternative approaches, including cell-based assays, organ-on-chip systems, and computational models. This regulatory shift accelerated substantially in 2025–2026: in April 2025, the FDA issued its Roadmap to Reducing Animal Testing in Preclinical Safety Studies, explicitly identifying organ-on-a-chip systems, advanced in vitro assays, and computational modeling as New Approach Methodologies (NAMs). In March 2026, the FDA released draft guidance providing drug developers with a framework for validating NAMs for use in regulatory submissions. In April 2026, the FDA reported that it had achieved its first-year goals under the roadmap and noted that more than 90% of drugs that clear animal studies historically fail to receive FDA approval, often because of safety or efficacy issues identified during human trials. These developments are strengthening the regulatory rationale for human-relevant platforms such as organ-on-chip and microphysiological systems.
Public investment in human-based research is also expanding. In April 2025, the NIH announced a new initiative to prioritize human-based research technologies and reduce reliance on animal models, while in July 2025 it directed new animal-model-related funding opportunities to also support human-focused approaches such as microphysiological systems, organoids, computational methods, and AI. In September 2025, NIH awarded contracts totaling US$87 million for the first three years of its Standardized Organoid Modeling Center, designed to develop standardized and reproducible organoid-based NAMs. In parallel, NIH's NCATS Tissue Chip for Drug Screening program has committed up to US$75 million to date toward tissue-chip development and validation. These investments, together with increasing pharmaceutical adoption and regulatory acceptance of human-relevant models, are strengthening the commercial foundation for organ-on-chip technologies across drug discovery, toxicity testing, disease modeling, and precision medicine.
Market dynamics
9 factors across 4 forcesIncreasing Demand for Alternatives to Animal Testing
Growing scientific, ethical, and regulatory pressure to reduce reliance on animal models is one of the primary drivers of organ-on-chip adoption. The FDA Modernization Act 2.0 and the FDA's subsequent roadmap toward making animal testing the exception rather than the norm within three to five years are directly expanding the addressable use cases for organ-on-chip platforms in regulatory-grade preclinical testing.
Rising R&D Costs in Drug Discovery
Pharmaceutical companies continue to face escalating drug development costs and high late-stage clinical trial failure rates driven by preclinical models that fail to predict human responses. Organ-on-chip platforms offer the potential to identify safety and efficacy issues earlier in the development pipeline, reducing costly late-stage failures and creating a strong economic incentive for adoption.
Growing Demand for Human-Relevant Preclinical Models
Traditional animal models frequently fail to accurately predict human drug responses due to interspecies physiological differences, contributing to costly clinical trial failures. Organ-on-chip platforms, built using human-derived cells, provide a more physiologically and clinically relevant testing environment, driving increasing pharmaceutical industry adoption.
Table of contents
15 chapters · 313 sections · 457 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Organ Type | Liver-on-Chip | Multi-Organ-on-Chip platforms |
| By Type | Single-Organ-on-Chip | Human-on-Chip platforms |
| By Product and Service | Products | Services |
| By Application | Drug Discovery & Development | Personalized & Precision Medicine |
| By End User | Pharmaceutical & Biotechnology Companies | Contract Research Organizations |
By Organ Type
- Liver-on-Chip is expected to account for the largest market share, reflecting the liver's central role in drug metabolism and its position as the most frequent site of drug-induced toxicity, making liver-on-chip models a priority application for hepatotoxicity and drug metabolism studies.
- However, Multi-Organ-on-Chip platforms are projected to register the fastest growth during the forecast period, driven by increasing pharmaceutical industry interest in modeling systemic drug distribution and inter-organ toxicity beyond single-organ testing.
By Type
- Single-Organ-on-Chip is expected to account for the largest market share, reflecting its more established validation base and broader current adoption across routine drug screening and toxicology applications.
- However, Human-on-Chip platforms are projected to register the fastest growth, driven by growing research investment in comprehensive, systemic physiological models capable of representing whole-body drug response.
By Product and Service
- Products are expected to account for the largest market share, reflecting sustained capital investment in organ-on-chip devices and instrumentation by pharmaceutical companies and research institutions building internal testing capabilities.
- However, Services are projected to register the fastest growth, driven by growing demand among smaller biotechnology companies and research organizations to access organ-on-chip capabilities through contract research and testing services without significant upfront capital investment.
By Application
- Drug Discovery & Development is expected to account for the largest market share, consistent with organ-on-chip technology's primary current use case in target validation, drug screening, and pharmacokinetic studies.
- However, Personalized & Precision Medicine is projected to register the fastest growth, driven by increasing use of patient-derived cell-based organ-on-chip models to predict individual treatment response.
By End User
- Pharmaceutical & Biotechnology Companies are expected to account for the largest market share, reflecting the technology's growing integration into preclinical drug development pipelines.
- However, Contract Research Organizations are projected to register the fastest growth, driven by increasing outsourcing of organ-on-chip testing and disease modeling services by pharmaceutical sponsors seeking specialized expertise without in-house capability investment.
Geographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of the global Organ-on-Chip Market. The region's leadership is underpinned by the presence of leading organ-on-chip technology developers, substantial NIH funding through the Tissue Chip for Drug Screening program, which has invested more than USD 140 million since 2012, and the FDA Modernization Act 2.0's direct regulatory pathway for organ-on-chip data in U.S. drug development submissions. The concentration of major pharmaceutical companies and their growing direct partnerships with organ-on-chip developers further reinforces the region's market leadership.
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR during the forecast period. The region's rapid growth is driven by expanding pharmaceutical and biotechnology R&D investment in China, Japan, South Korea, and India, growing academic research capacity in microfluidics and tissue engineering, and increasing government support for advanced life sciences research infrastructure across the region's major biotechnology hubs.
Competitive landscape
The global Organ-on-Chip Market is highly fragmented, with competition among specialized organ-on-chip platform developers, academic spin-off companies, and microfluidics technology providers. Companies compete primarily on platform validation data, breadth of organ models offered, ease of use and workflow integration, regulatory qualification progress, and strategic partnerships with pharmaceutical sponsors.
Leading market participants are investing in expanding their organ model portfolios toward multi-organ and human-on-chip platforms, pursuing FDA qualification pathways such as the Innovative Science and Technology Approaches for New Drugs program, and forming strategic partnerships and collaborations with major pharmaceutical companies to co-develop custom disease models and validate platform performance against clinical outcomes. Capacity expansions, new product launches, and pharmaceutical industry collaborations remain key strategies adopted by major vendors in this early-stage, high-growth market.
The report provides a comprehensive competitive assessment of the leading companies operating in the global Organ-on-Chip Market. The key players profiled in the report include Emulate, Inc., MIMETAS B.V., CN Bio Innovations Ltd., TissUse GmbH, InSphero AG, Nortis, Inc., AlveoliX AG, Hesperos, Inc., Kirkstall Ltd., Cherry Biotech, AIM Biotech Pte. Ltd., SynVivo, Inc., Quris-AI, and Altis Biosystems, Inc.
- Emulate, Inc.
- MIMETAS B.V.
- CN Bio Innovations Ltd.
- TissUse GmbH
- InSphero AG
- Nortis, Inc.
- AlveoliX AG
- Hesperos, Inc.
- Kirkstall Ltd.
- Cherry Biotech
- AIM Biotech Pte. Ltd.
- SynVivo, Inc.
- Quris-AI
- Altis Biosystems, Inc
Frequently asked questions
The global Organ-on-Chip Market is estimated at USD 342.5 million in 2026
Cite this report
Meticulous Research. (2026). Organ-on-Chip Market - Global Opportunity Analysis and Industry Forecast to 2036 (Report No. MR-2149). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/organ-on-chip-market-6832